Nature Communications (Jun 2024)
Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis
- Julia Krämer,
- Carolin Balloff,
- Margit Weise,
- Valeria Koska,
- Yannik Uthmeier,
- Isabell Esderts,
- Mai Nguyen-Minh,
- Moritz Zimmerhof,
- Alex Hartmann,
- Michael Dietrich,
- Jens Ingwersen,
- John-Ih Lee,
- Joachim Havla,
- Tania Kümpfel,
- Martin Kerschensteiner,
- Vivien Häußler,
- Christoph Heesen,
- Jan-Patrick Stellmann,
- Hanna G. Zimmermann,
- Frederike C. Oertel,
- Marius Ringelstein,
- Alexander U. Brandt,
- Friedemann Paul,
- Orhan Aktas,
- Hans-Peter Hartung,
- Heinz Wiendl,
- Sven G. Meuth,
- Philipp Albrecht
Affiliations
- Julia Krämer
- Department of Neurology with Institute of Translational Neurology, University Hospital Münster
- Carolin Balloff
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Margit Weise
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Valeria Koska
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Yannik Uthmeier
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Isabell Esderts
- Department of Neurology with Institute of Translational Neurology, University Hospital Münster
- Mai Nguyen-Minh
- Department of Neurology with Institute of Translational Neurology, University Hospital Münster
- Moritz Zimmerhof
- Department of Neurology with Institute of Translational Neurology, University Hospital Münster
- Alex Hartmann
- Hanseatic Statistics
- Michael Dietrich
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Jens Ingwersen
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- John-Ih Lee
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Joachim Havla
- Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians University München
- Tania Kümpfel
- Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians University München
- Martin Kerschensteiner
- Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians University München
- Vivien Häußler
- Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Hospital Hamburg-Eppendorf
- Christoph Heesen
- Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Hospital Hamburg-Eppendorf
- Jan-Patrick Stellmann
- Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Hospital Hamburg-Eppendorf
- Hanna G. Zimmermann
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Frederike C. Oertel
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Marius Ringelstein
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Alexander U. Brandt
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Friedemann Paul
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
- Orhan Aktas
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Hans-Peter Hartung
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Heinz Wiendl
- Department of Neurology with Institute of Translational Neurology, University Hospital Münster
- Sven G. Meuth
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- Philipp Albrecht
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf
- DOI
- https://doi.org/10.1038/s41467-024-49309-7
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 16
Abstract
Abstract Retinal optical coherence tomography has been identified as biomarker for disease progression in relapsing-remitting multiple sclerosis (RRMS), while the dynamics of retinal atrophy in progressive MS are less clear. We investigated retinal layer thickness changes in RRMS, primary and secondary progressive MS (PPMS, SPMS), and their prognostic value for disease activity. Here, we analyzed 2651 OCT measurements of 195 RRMS, 87 SPMS, 125 PPMS patients, and 98 controls from five German MS centers after quality control. Peripapillary and macular retinal nerve fiber layer (pRNFL, mRNFL) thickness predicted future relapses in all MS and RRMS patients while mRNFL and ganglion cell-inner plexiform layer (GCIPL) thickness predicted future MRI activity in RRMS (mRNFL, GCIPL) and PPMS (GCIPL). mRNFL thickness predicted future disability progression in PPMS. However, thickness change rates were subject to considerable amounts of measurement variability. In conclusion, retinal degeneration, most pronounced of pRNFL and GCIPL, occurs in all subtypes. Using the current state of technology, longitudinal assessments of retinal thickness may not be suitable on a single patient level.
